Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors
Published: 07 September 2020
-
Views:
893
-
Likes:
7
-
Views:
893
-
Likes:
7
Overview
This educational symposium first broadcast at the ESC Congress 2020 discusses how SGLT2 inhibitors should be utilised by cardiologists in everyday practice
Learning objectives
- Understand current guidelines and utilisation of SGLT2i
- Describe the potential mechanism of benefit of SGLT2i
- Initiate and manage SGLT2i in appropriate patients
More from this programme
Part 1
Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice
Part 2
SGLT2i are Cardiovascular Drugs
| 1 session | |
| SGLT2i are Cardiovascular Drugs | Watch now |
Part 3
Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?
Part 4
Case Discussion
| 1 session | |
| Case Discussion | Watch now |
Part 5
A Follow-up Discussion to the ESC 2020 Session
Faculty Biographies
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.